Answers are grounded in this paper and cite their sources.
Randomized trial shows that HLA-B*5701 screening reduces hypersensitivity reactions in diverse populations, suggesting safer drug use.
HLA-B*5701 screening reduced the risk of hypersensitivity reaction to abacavir. In predominantly white populations, similar to the one in this study, 94% of patients do not carry the HLA-B*5701 allele and are at low risk for hypersensitivity reaction to abacavir. Our results show that a pharmacogenetic test can be used to prevent a specific toxic effect of a drug. (ClinicalTrials.gov number, NCT00340080.)
No takes yet. Share an insight, caveat, or question.
Mallal et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: